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Introduction {#sec1}
============

NMDARs (N-methyl-D-aspartate \[NMDA\] receptors) are glutamate-gated cation channels with high Ca^2+^ permeability that play key roles in CNS processes, such as synaptic transmission, learning and memory, development, neuroprotective signaling, and redox balance, as well as in neurodegenerative and neurological disorders ([@bib3], [@bib6], [@bib7], [@bib39]). Most NMDARs contain two obligate GluN1 subunits and two GluN2 subunits, of which there are four types (2A--D), with GluN2A and GluN2B being predominant in the forebrain. The importance of the identity of NMDAR subtypes (GluN2A versus GluN2B) in humans is illustrated by the phenotypes of patients with mutations in the genes that encode them (*GRIN2A* and *GRIN2B*), which include intellectual disability, autism, epilepsy, and schizophrenia ([@bib9], [@bib21]). The GluN2 subtype dictates NMDAR biophysical properties, including agonist affinity, open probability, and deactivation kinetics ([@bib39], [@bib57]), thus influencing the downstream consequences of NMDAR activation, such as the properties of plasticity and metaplasticity in the cortex ([@bib13], [@bib40]). In addition, NMDAR composition can influence downstream NMDAR signaling to synaptic plasticity, cognition, and excitotoxicity by virtue of their highly divergent cytoplasmic C-terminal domains (CTDs) ([@bib33], [@bib48], [@bib49]). During forebrain development, there is a shift in NMDAR subunit composition, from near-exclusively GluN2B-containing NMDARs to NMDARs containing a significant GluN2A contribution, e.g., GluN1~2~-GluN2A~2~ diheteromeric receptors and GluN1~2~-GluN2A-GluN2B triheteromeric receptors ([@bib57]). This has been referred to as the "switch" in composition, which is partly experience dependent and takes place over postnatal weeks 2--5 in mice.

A prominent model for the mechanism by which GluN2A becomes incorporated into NMDARs at the expense of GluN2B involves a series of phosphorylation events centered on the CTD of GluN2B (CTD^2B^) and initiated by CaMKIIα binding to its GluN2B-specific interaction site ([@bib32], [@bib50], [@bib51]). CaMKIIα has been proposed to recruit casein kinase 2 (CK2) to phosphorylate CTD^2B^ at serine-1480, leading to the dissociation of the MAGUK-Fyn complex and reduction in CTD^2B^ tyrosine-1472 phosphorylation (a target of Fyn), destabilizing GluN2B's presence at the synapse and ultimately triggering AP-2-mediated endocytosis ([@bib28], [@bib50], [@bib51]). Because this model is based on observations of the properties of ectopically expressed mutant subunits, we wanted to gain insight into the role of GluN2B CTD-specific sequences in the developmental switch of endogenous NMDAR subunits and have approached this by studying receptors that have been modified at the genomic level.

Results {#sec2}
=======

Mutation of the GluN2B CaMKII Site Influences Phosphorylation of Its CTD {#sec2.1}
------------------------------------------------------------------------

To study the role of the endogenous CTD^2B^ CaMKII binding site, we generated a knockin mouse, containing three mutations in the GluN2B CTD^2B^ sub-region (L1298A/R1300N/S1303D), hereafter referred to as GluN2B^ΔCaMKII^ ([Figures 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}A). The combined L1298A/R1300N mutation is sufficient to abrogate CaMKII binding to GluN2B, as has the additional S1303D mutation *in vitro* ([@bib53]), which mimics the CaMKII-dependent phosphorylation event that inhibits its own binding ([@bib53]). The homozygote GluN2B^ΔCaMKII/ΔCaMKII^ mice were healthy and fertile, but to provide wild-type controls for the GluN2B^ΔCaMKII/ΔCaMKII^ neurons within the same litter, our approach was to perform heterozygous intercrosses. Co-immunoprecipitation of NMDARs (using an N-terminal antibody to GluN2B) with CaMKIIα was reduced by around 40% ([Figures 1](#fig1){ref-type="fig"}H and 1I), a reduction similar to that observed with a previously described GluN2B L1298A/R1300N knockin ([@bib20]). The remaining co-immunoprecipitation may be due to CaMKIIα association with GluN1 ([@bib29]).Figure 1The GluN2B CaMKII Site Is Dispensable for the Developmental Switch *In Vitro*(A) Schematic of the GluN2B^ΔCaMKII^ amino acid changes.(B and C) Altered GluN2B phosphorylation in GluN2B^ΔCaMKII/ΔCaMKII^ neurons. Cortical neuronal extracts were prepared and analyzed by western blot with the indicated antibodies, normalized to total GluN2B. (B) shows quantitation (mean ± SEM here and throughout), and (C) shows an example. ^∗^p \< 0.05 versus GluN2B^+/+^ (n = 4).(D) NMDAR current density at the indicated ages for GluN2B^WT/WT^ and GluN2B^ΔCaMKII/ΔCaMKII^ neurons. ^∗^p \< 0.05 versus DIV7 or DIV8 of the same genotype; two-way ANOVA plus Sidak's post hoc test (GluN2B^WT/WT^: n = 14 \[DIV7 or DIV8\], n = 18 \[DIV14--18\]; GluN2B^ΔCaMKII/ΔCaMKII^: n = 15 \[DIV7 or DIV8\], n = 17 \[DIV14--18\]).(E) Extrasynaptic NMDAR currents were measured in GluN2B^WT/WT^ and GluN2B^ΔCaMKII/ΔCaMKII^ neurons (n = 8 per genotype).(F and G) GluN2A and GluN2B expression analyzed by western blot at DIV8 and DIV16 for GluN2B^WT/WT^ and GluN2B^ΔCaMKII/ΔCaMKII^ neurons. (F) shows quantitation and (G) shows an example. ^∗^p \< 0.05 versus DIV8 of the same genotype; two-way ANOVA plus Sidak's post hoc test (n = 8).(H and I) Neocortices of GluN2B^WT/WT^ and GluN2B^ΔCaMKII/ΔCaMKII^ mice were subjected to immunoprecipitation with an antibody to the N terminus of GluN2B, followed by analysis of GluN2B and CaMKIIα content. (H) shows an example and (I) shows quantitation. ^∗^p \< 0.05; n = 8 per genotype.(J) Percentage blockade of NMDAR currents by ifenprodil (3 μM) at the indicated stages for GluN2B^WT/WT^ and GluN2B^ΔCaMKII/ΔCaMKII^ neurons. ^∗^p \< 0.05 versus DIV7 or DIV8 of the same genotype; two-way ANOVA plus Sidak's post hoc test (GluN2B^WT/WT^: n = 14 \[DIV7 or DIV8\], n = 18 \[DIV14--18\]; GluN2B^ΔCaMKII/ΔCaMKII^: n = 15 \[DIV7 or DIV8\], n = 17 \[DIV14--18\]).(K and L) Percentage potentiation of NMDAR currents by 100 μM spermine was measured at the indicated stages for GluN2B^WT/WT^ and GluN2B^ΔCaMKII/ΔCaMKII^ neurons. ^∗^p \< 0.05 versus DIV7 or DIV8 of the same genotype; two-way ANOVA plus Sidak's post hoc test (GluN2B^WT/WT^: n = 13 \[DIV7 or DIV8\], n = 18 \[DIV14--18\]; GluN2B^ΔCaMKII/ΔCaMKII^: n = 18 \[DIV7 or DIV8\], n = 14 \[DIV14--18\]). (K) shows quantitation and (L) shows example traces; scale bar: 200 pA/2 s.(M and N) Neocortical extracts from P14 and P28 mice were analyzed for GluN2A expression, normalized to β-actin. (M) shows quantitation and (N) shows an example. ^∗^p \< 0.05 versus P14 of the same genotype; two-way ANOVA plus Sidak's post hoc test (n = 8).(O and P) Post-synaptic density (PSD) extracts from P14 and P28 mice of the indicated genotype were analyzed for GluN2A and GluN2B expression, normalized to β-actin, and the ratio calculated. (O) shows quantitation and (P) shows an example. ^∗^p \< 0.05 versus P14 of the same genotype; two-way ANOVA plus Sidak's post hoc test (n = 8).

We first studied CTD^2B^ phosphorylation in GluN2B^ΔCaMKII/ΔCaMKII^ neurons, observing a reduction in CTD^2B^ Ser-1480 phosphorylation and an increase in Tyr-1472 phosphorylation in cortical neurons at both day in vitro 9 (DIV9) and DIV16 ([Figures 1](#fig1){ref-type="fig"}B and 1C), consistent with a role for CaMKII in recruiting casein kinase 2 to CTD^2B^, causing a reduction in Fyn recruitment ([@bib28], [@bib50], [@bib51]). As expected, GluN2B^ΔCaMKII/ΔCaMKII^ was also immunonegative for the phospho-Ser-1303 site ([Figure 1](#fig1){ref-type="fig"}C).

It has been shown that overexpressing constitutively active Fyn enhances synaptic localization of wild-type GluN2B by around 15% in a Tyr-1472-dependent manner ([@bib41]), so we studied synaptic versus extrasynaptic localization. At an age (DIV9) when NMDAR currents are almost entirely mediated by GluN2B-containing NMDARs, GluN2B^ΔCaMKII/ΔCaMKII^ neurons were found to have a similar proportion of extrasynaptic NMDAR currents as neurons from GluN2B^WT/WT^ littermates ([Figure 1](#fig1){ref-type="fig"}E). We also measured synaptic and extrasynaptic GluN2B levels in the neocortex ([Figure S1](#mmc1){ref-type="supplementary-material"}B) and the hippocampus ([Figure S1](#mmc1){ref-type="supplementary-material"}C) of P28 GluN2B^ΔCaMKII/ΔCaMKII^ mice, using biochemical fractionation of synaptosome preparations ([@bib33]), again revealing no genotype-dependent differences. Thus, the relatively modest changes in CTD phosphorylation in GluN2B^ΔCaMKII/ΔCaMKII^ neurons appeared to be insufficient to significantly affect NMDAR localization. This is consistent with observations that complete exchange of the GluN2B CTD with that of GluN2A does not influence synaptic versus extrasynaptic localization ([@bib33]).

The GluN2B CaMKII Site Is Dispensable for the Developmental Switch *In Vitro* and *In Vivo* {#sec2.2}
-------------------------------------------------------------------------------------------

To investigate the role of the endogenous CTD^2B^ CaMKII in the developmental change in NMDAR subunit composition, we first studied primary cortical neurons, which show increased GluN2A incorporation during the 2nd week *in vitro*. NMDAR current density in the cortical neurons increased between DIV8 and DIV14--18 and was not different in GluN2B^ΔCaMKII/ΔCaMKII^ neurons versus GluN2B^WT/WT^ neurons ([Figure 1](#fig1){ref-type="fig"}D). Moreover, we observed the expected developmental increase in the GluN2A:GluN2B ratio (protein) in both genotypes ([Figures 1](#fig1){ref-type="fig"}F and 1G). To assess changes in subunit composition, a standard approach is to assess the sensitivity of NMDAR currents to a GluN2B-selective antagonist, such as ifenprodil. We observed a drop in the ifenprodil sensitivity of NMDAR currents between DIV8 and DIV14--18 in GluN2B^WT/WT^ neurons as expected ([Figure 1](#fig1){ref-type="fig"}J) but also a similar drop in currents from GluN2B^ΔCaMKII/ΔCaMKII^ neurons.

The degree of the drop in ifenprodil sensitivity is limited by the fact that GluN1~2~-GluN2B~2~ diheteromeric receptors are only maximally blocked by around 80%, and GluN1~2~-GluN2A-GluN2B triheteromeric receptors, which contribute to NMDAR currents in mature forebrain neurons, are still blocked by around 30% ([@bib54]). We therefore took an additional approach, exploiting the strong GluN2B-specific potentiation of NMDAR currents by spermine at −30 mV (pH 6.5; [@bib36]), observed in GluN1~2~-GluN2B~2~ NMDARs, but not GluN1~2~-GluN2A-GluN2B or GluN1~2~-GluN2A~2~ NMDARs ([@bib54]). We validated the approach in neurons from a GluN2A^−/−^ rat line we recently generated: cortical neurons from GluN2A^+/+^, but not GluN2A^−/−^, littermates showed a developmental drop in spermine potentiation of NMDAR currents ([Figure S1](#mmc1){ref-type="supplementary-material"}D). Applying this technique to GluN2B^WT/WT^ versus GluN2B^ΔCaMKII/ΔCaMKII^ mouse cortical neurons, we observed a developmental drop in spermine potentiation in GluN2B^WT/WT^ neurons, which was equally strong in GluN2B^ΔCaMKII/ΔCaMKII^ neurons ([Figures 1](#fig1){ref-type="fig"}K and 1L). Collectively, these data show that the GluN2B CaMKII site is not required for normal developmental changes in NMDAR subunit composition in primary cortical neurons.

An advantage of employing a knockin mouse model is that the role of the GluN2B CaMKII site can be studied *in vivo*. In protein extracts from the neocortex and hippocampus of GluN2B^WT/WT^ and GluN2B^ΔCaMKII/ΔCaMKII^ mice, we observed the expected increase in GluN2A expression between postnatal day 14 (P14) and P28 ([Figures 1](#fig1){ref-type="fig"}M, 1N, and [S1](#mmc1){ref-type="supplementary-material"}E). We prepared postsynaptic density (PSD) fractions and measured the GluN2A:GluN2B ratio, finding that the expected developmental increase in the GluN2A:GluN2B ratio in synaptic NMDARs in GluN2B^WT/WT^ mice was also observed in GluN2B^ΔCaMKII/ΔCaMKII^ mice in the neocortex ([Figures 1](#fig1){ref-type="fig"}O and 1P) and hippocampus ([Figure S1](#mmc1){ref-type="supplementary-material"}F). Thus, targeted mutation of the endogenous GluN2B CaMKII site has no apparent effect on the developmental shift in synaptic NMDAR subunit composition.

The GluN2B CaMKII Site Is Dispensable for Synaptogenesis and Theta Burst LTP {#sec2.3}
----------------------------------------------------------------------------

The GluN2B CaMKII site has been proposed to be important for synaptic NMDAR signaling to the ERK1/2 pathway: overexpressing a CaMKIIα mutant defective in GluN2B binding reduces NMDAR-dependent ERK1/2 activation ([@bib16]). We analyzed basal ERK1/2 activity in DIV9 cortical cultures, which is maintained by synaptic NMDAR activity (sensitive to TTX and MK-801) and is partly CaM-kinase-dependent (sensitive to KN-62; [@bib10], [@bib16]). Studying wild-type, GluN2B^ΔCaMKII/ΔCaMKII^, and GluN2B^2A(CTR)/2A(CTR)^ neurons, we found a significant effects of both TTX, MK-801, and KN-62 on basal levels, confirming previous observations, but no genotype-dependent differences in ERK1/2 activity ([Figures 2](#fig2){ref-type="fig"}A and 2B). To test whether any GluN2B-specific CTD sequences are needed for signaling to ERK1/2, we performed the same experiment on neurons cultured from GluN2B^2A(CTR)/2A(CTR)^ pups, a knockin line in which GluN2B CTD has been replaced by that of GluN2A ([@bib33], [@bib49]). Compared to neurons cultured from GluN2B^WT/WT^ littermates, we again observed no genotype-dependent differences in activity-dependent ERK1/2 activity ([Figures 2](#fig2){ref-type="fig"}A and 2C), suggesting that this does not have a requirement for GluN2B-specific CTD sequences.Figure 2The GluN2B CaMKII Binding Site Is Dispensable for Theta Burst LTP(A--C) Activity-dependent signaling to ERK1/2 does not require GluN2B CTD-specific sequences. DIV9 cortical neurons of the indicated genotypes were treated with TTX (500 nM), KN-62 (10 μM), or MK-801 (10 μM) for 1 hr, after which protein extracts were made and subjected to western blot analysis for phospho-ERK1/2 levels, normalized to total ERK1/2. (A) shows quantitation and (B) and (C) show example blots.^∗^p \< 0.05 two-way ANOVA plus Dunnett's post hoc test. No genotype-dependent effects were observed (p = 0.39) or genotype-drug interactions (p = 0.16; n = 8 GluN2B^WT/WT^; n = 4 GluN2B^ΔCaMKII/ΔCaMKII^; n = 4 GluN2B^2A(CTR)/2A(CTR)^).(D--F) Cumulative probability plots show amplitude (D) and frequency (E) of miniature EPSCs in GluN2B^WT/WT^ and GluN2B^ΔCaMKII/ΔCaMKII^ slices. Results are from 11 cells from 3 GluN2B^WT/WT^ mice and 13 cells from 3 GluN2B^ΔCaMKII/ΔCaMKII^ mice; p = 0.75 (amplitude); p = 0.94 (frequency); unpaired t test. (F) shows example traces. Scale bar: 10 pA/100 ms.(G) NMDAR:AMPAR EPSC ratios at −80 and +40 mV was measured in GluN2B^WT/WT^ (n = 25; 4 mice) and GluN2B^ΔCaMKII/ΔCaMKII^ (n = 30; 4 mice) neurons (unpaired t test; p = 0.95).(H) Weighted time constant (τw) for the decay of EPSCs recorded in (A) at +40 mV was determined using double exponential fits (unpaired t test; p *=* 0.63).(I) Example traces. Scale bar: 100 pA/20 ms.(J and K) Theta-burst stimulation elicited pathway-specific LTP of synaptic transmission in hippocampal CA1 area. Normalized magnitude of this potentiation 60--65 min after LTP induction did not differ significantly in GluN2B^WT/WT^ mice (29 slices; n = 9) compared to GluN2B^ΔCaMKII/ΔCaMKII^ (35 slices; n = 11); p = 0.162 (two-way nested ANOVA). (J) shows quantitation of data and (K) shows example traces before and after LTP induction.(K) Traces show example fEPSP traces immediately before and 1 hr after theta-burst stimulation. Scale bar: 0.5 mV/2 ms.

An additional putative role of the GluN2B CaMKII interaction site is in excitatory synaptogenesis, based on the effects of overexpression of a GluN2B mutant impaired in CaMKII binding (RS/QD: R1300Q;S1303D; [@bib18]). Analysis of miniature excitatory postsynaptic current (mEPSC) size and frequency revealed that they were unaltered in GluN2B^ΔCaMKII/ΔCaMKII^ mice ([Figures 2](#fig2){ref-type="fig"}D--2F). Consistent with this, field excitatory postsynaptic potential (fEPSP) recordings by multi-electrode array revealed similar input-output curves in both genotypes ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Also, a comparison of fEPSP slopes and presynaptic fiber volley amplitudes in fEPSP recordings by conventional glass electrodes also revealed no difference between genotypes ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C). Given that CaMKIIα activity is implicated in synaptogenesis, we looked at the levels of phospho-Thr286 CaMKIIα in hippocampal postsynaptic densities and found them to be similar in mice of both genotypes also ([Figure S2](#mmc1){ref-type="supplementary-material"}D). We also probed the NMDAR properties and subunit composition in the hippocampal CA1 synapses. NMDAR:AMPAR ratios were similar in neurons of GluN2B^WT/WT^ and GluN2B^ΔCaMKII/ΔCaMKII^ mice ([Figure 2](#fig2){ref-type="fig"}G), as was the decay kinetics of EPSCs recorded at +40 mV ([Figures 2](#fig2){ref-type="fig"}H and 2I), which is dictated by the dissociation rate of glutamate from NMDARs and is slower for GluN2B than GluN2A ([@bib39]).

An additional putative role of the GluN2B CaMKII interaction site is in hippocampal theta burst (TBS) long-term potentiation ([@bib2]), known to involve both CaMKII and ERK1/2 activation ([@bib56], [@bib2], [@bib26]). We found that TBS-long term potentiation (LTP) was not significantly different in GluN2B^ΔCaMKII/ΔCaMKII^ versus GluN2B^WT/WT^ slices ([Figures 2](#fig2){ref-type="fig"}J and 2K; n = 8 animals per genotype), suggesting that the GluN2B CaMKII site is not critical for this form of NMDAR-dependent synaptic plasticity.

Distinct GluN2 CTDs Are Not Required for the NMDAR Developmental Switch {#sec2.4}
-----------------------------------------------------------------------

We next addressed a more general question as to whether the NMDAR subunit switch has any requirement for GluN2-specific CTD sequences. To investigate this, we utilized another knockin mouse, GluN2A^2B(CTR)^ ([Figure 3](#fig3){ref-type="fig"}A), in which we replaced the exon encoding the CTD of GluN2A with that of GluN2B ([@bib49]), meaning that both GluN2A and GluN2B have the same CTD. NMDAR current density in GluN2A^2B(CTR)/2B(CTR)^ neurons was found to be no different to GluN2A^WT/WT^ neurons ([Figure 3](#fig3){ref-type="fig"}B). Importantly, the developmental drop in NMDAR current potentiation by spermine was identical in GluN2A^2B(CTR)/2B(CTR)^ and GluN2A^WT/WT^ neurons ([Figures 3](#fig3){ref-type="fig"}C and 3D), as was ifenprodil sensitivity of NMDAR currents ([Figure S3](#mmc1){ref-type="supplementary-material"}A). We also observed no difference in the synaptic versus extrasynaptic localization of NMDARs: in DIV14--18 neurons, neither the proportion of extrasynaptic NMDAR currents nor their sensitivity to ifenprodil was different in GluN2A^2B(CTR)/2B(CTR)^ neurons compared to GluN2A^WT/WT^ neurons ([Figures S3](#mmc1){ref-type="supplementary-material"}B and S3C). Moreover, the developmental increase in GluN2A expression in the neocortex and hippocampus of GluN2A^2B(CTR)/2B(CTR)^ and GluN2B^WT/WT^ mice was indistinguishable ([Figures 3](#fig3){ref-type="fig"}E, 3F, and [S3](#mmc1){ref-type="supplementary-material"}D). Furthermore, the developmental increase in the synaptic GluN2A:GluN2B ratio in cortical ([Figures 3](#fig3){ref-type="fig"}G and 3H) and hippocampal ([Figure S3](#mmc1){ref-type="supplementary-material"}E) tissue was also similar. Thus, even when GluN2A and GluN2B possess identical CTDs, the developmental shift in NMDAR subunit composition, and their targeting to synaptic or extrasynaptic locations, proceeds normally *in vitro* and *in vivo*.Figure 3Distinct GluN2 CTDs Are Not Required for the 2B-to-2A Switch(A) Schematic illustrating the C-terminal domain exchange in the GluN2A^2B(CTR)/2B(CTR)^ mouse.(B) NMDAR current density in GluN2A^WT/WT^ (n = 30) and GluN2A^2B(CTR)/2B(CTR)^ (n = 24) neurons, recorded DIV14--18.(C and D) Percentage potentiation of NMDAR currents by 100 μM spermine was measured in GluN2A^WT/WT^ and GluN2A^2B(CTR)/2B(CTR)^ neurons. ^∗^p \< 0.05 versus DIV7 or DIV8 of the same genotype; two-way ANOVA plus Sidak's post hoc test (GluN2A^WT/WT^: n = 19 \[DIV7 or DIV8\], n = 18 \[DIV14--18\]; GluN2A^2B(CTR)/2B(CTR)^: n = 16 \[DIV7 or DIV8\], n = 17 \[DIV14--18\]). (C) shows quantitation of data and (D) shows example traces; scale bar: 200 pA/2 s.(E and F) Neocortical extracts from P14 and P28 mice of the indicated genotype were analyzed for GluN2A expression, normalized to β-actin. ^∗^p \< 0.05 versus P14 of the same genotype; two-way ANOVA plus Sidak's post hoc test (n = 8). (E) shows quantitation and (F) shows example blots.(G and H) PSD extracts from P14 and P28 mice of the indicated genotype were analyzed for GluN2A and GluN2B expression, normalized to β-actin, and the ratio calculated and scaled such that the ratio at P14 for WT = 1. ^∗^p \< 0.05 versus P14 of the same genotype; two-way ANOVA plus Sidak's post hoc test (n = 8). (G) shows quantitation and (H) shows an example blot.

Increased Expression of GluN2A Is a Key Determinant of the Shift in Subunit Composition {#sec2.5}
---------------------------------------------------------------------------------------

It has been proposed that epigenomic repression of GluN2B is a contributing factor to the developmental increase in GluN2A:GluN2B ratio in the hippocampus ([@bib46]). However, the extent to which GluN2B repression drives the subunit switch in the cortex, compared to GluN2A upregulation, is unclear. We recently showed that GluN2B protein levels are around 10-fold higher than GluN2A in the adult cortex ([@bib17]), suggesting that the GluN2A:GluN2B ratio is more sensitive to an increase in GluN2A than an equivalent fall in GluN2B. We measured total GluN2B expression in the neocortex at P14 and P28 from wild-type, GluN2A^2B(CTR)/2B(CTR)^, and GluN2B^ΔCaMKII/ΔCaMKII^ mice and found no evidence for decreasing GluN2B expression ([Figures 4](#fig4){ref-type="fig"}A--4D), consistent with other studies on the cortex ([@bib30], [@bib52]). Thus, the developmental shift in NMDAR subunit composition in the developing cortex can commence without the substantial repression of GluN2B expression, as well as without GluN2B CTD-dependent removal of GluN2B-containing NMDARs from the synapse ([Figure 3](#fig3){ref-type="fig"}). This suggests that the overriding factor is simply the increasing level of GluN2A expression. Indeed, by analyzing spermine potentiation of currents in DIV14 and DIV15 cortical neurons from GluN2A^+/+^, GluN2A^+/−^, and GluN2A^−/−^ rats, we observed a negative correlation with gene copy number ([Figures 4](#fig4){ref-type="fig"}H and 4I). This points to impairment in the replacement of GluN1~2~-GluN2B~2~ NMDARs with GluN1~2~-GluN2A-GluN2B and GluN1~2~-GluN2A~2~ NMDARs, due to haploinsufficiency of the *Grin2a* gene, suggesting that GluN2A levels are the limiting factor in dictating the switch. As expected, the reverse was also found: GluN2A overexpression in young rat or mouse neurons has a very modest effect on NMDAR currents ([@bib33]) but resulted in a very strong reduction of NMDAR current potentiation by spermine ([Figures 4](#fig4){ref-type="fig"}E--4G). Thus, a major determinant of the developmental shift in NMDAR subunit composition is the increasing expression of GluN2A.Figure 4GluN2A Expression Is Sufficient to Displace GluN2B from NMDARs(A--D) Total GluN2B expression was measured in extracts from the neocortex at the indicated stages for the indicated genotypes (n = 8 per genotype). (A) and (B) show quantitation and example blots, respectively, for GluN2A^WT/WT^ versus GluN2A^2B(CTR)/2B(CTR)^. (C) and (D) show quantitation and example blots, respectively, for GluN2A^WT/WT^ vs. GluN2B^ΔCaMKII/ΔCaMKII^.(E--G) Ectopic GluN2A expression is sufficient to displace GluN2B from NMDARs. Young mouse (E and F) and rat (G) neurons at DIV7 were transfected with a control (β-globin) or GluN2A-encoding vector and spermine (100 μM) potentiation of NMDAR currents measured 72 hr later. ^∗^p \< 0.05 (F: n = 10 of both condition; G: n = 8 control; n = 10 GluN2A).(H) Percentage potentiation of NMDAR currents by spermine (200 μM) in DIV15 or DIV16 rat cortical neurons was measured at the indicated stages for GluN2A^+/+^, GluN2A^+/−^, and GluN2A^−/−^ genotypes. Person r correlation coefficient: −0.9954; p = 0.031 (one-tailed test); n = 12 cells per genotype.(I) Western blot illustrating GluN2A expression in GluN2A^+/+^, GluN2A^+/--^, and GluN2A^--/--^ neurons.(I) A western blot confirming the absence of GluN2A expression in GluN2A^−/−^ and an intermediate expression level in GluN2A^+/−^ neurons.

Discussion {#sec3}
==========

Probing Channel Domain Function Using Knockin Mouse Models {#sec3.1}
----------------------------------------------------------

Our experiments point to the value of probing putative signaling domains within ion channels and receptors by targeted genetic approaches, as opposed to reliance on ectopic expression of mutant receptors. For example, compared to overexpression of wild-type GluN2B, overexpression of the GluN2B CaMKII site R1300Q/S1303D mutant in cultured hippocampal neurons impairs functional synaptogenesis, assayed by mEPSC frequency and spine number ([@bib18]). In contrast, we found normal mEPSC size and frequency in hippocampal slices of GluN2B^ΔCaMKII/ΔCaMKII^ mice, consistent with a report of normal synaptogenesis in an independently created CaMKII site mutant knockin mouse ([@bib20]). Furthermore, a recent study proposed that GluN2B's CamKIIα interaction site is important for correct basal AMPA-receptor-mediated synaptic transmission ([@bib25]), based on results of acute virus-delivered CRISPR deletion of the endogenous GluN2B gene in slice culture and ectopic expression of mutant versus wild-type (WT) subunits. In contrast, we see normal basal hippocampal synaptic transmission in GluN2B^ΔCaMKII/ΔCaMKII^ mice ([Figures 2](#fig2){ref-type="fig"} and [S2](#mmc1){ref-type="supplementary-material"}), again consistent with the observations made previously in a different knockin model ([@bib20]). Furthermore, overexpression of another GluN2B CaMKII site mutant (S1303E) led to a higher increase in GluN2B surface expression than WT GluN2B overexpression ([@bib51]), whereas we found normal NMDAR currents in GluN2B^ΔCaMKII/ΔCaMKII^ neurons. Moreover, expression of the CaMKII site mutant of GluN2B increased the GluN2B:GluN2A ratio at functional NMDARs in slice cultures, compared to the wild-type GluN2B, as measured by studying the EPSC decay constant ([@bib51]). In contrast, our recordings in acute hippocampal slices revealed unaltered EPSC decay constants in GluN2B^ΔCaMKII/ΔCaMKII^ mice, indicative of a normal synaptic GluN2B:GluN2A ratio, confirmed by biochemical fractionation. What could explain the discrepancy between observations based on knockin mouse lines versus overexpression of mutant subunits? One difference is that the latter may alter the relative stoichiometry of GluN2B and CaMKIIα, which could influence CaMKIIα interactions in the PSD. In the rat brain PSD, CaMKIIα is 50 times more abundant than GluN2B and 35- to 100-fold more abundant than GluN1 ([@bib31], [@bib11]). As such, mutating the endogenous GluN2B CaMKIIα site in a knockin is unlikely to influence the total synaptic or PSD-localized CaMKIIα. However, overexpression of GluN2B and mutant variants could alter the stoichiometric balance and cause the interaction of GluN2B with a greater proportion of CaMKIIα at the synapse and elsewhere. Of note, however, we did find that germline mutation of the GluN2B CaMKII site rendered neurons less vulnerable to excitotoxic insults (unpublished observation), consistent with previous findings based on overexpression of mutant subunits lacking this site ([@bib55]). Thus, results from ectopic subunit expression are not always in disagreement with conclusions derived from equivalent knockin models.

Although the GluN2B CaMKII site may have a limited role in the general developmental subunit switch in the cortex, it remains a possibility that it plays a role in more specialized situations, such as the experience or activity-dependent element of the 2B-to-2A switch that occurs in the developing visual cortex ([@bib44]). It will be of interest to determine whether this process has a requirement for GluN2 CTD subtype-specific events, particularly because overexpression studies have implicated the GluN2B CaMKII site in activity-dependent subunit switching ([@bib51]).

Additionally, although our study argues against a role for the GluN2B CaMKII site-dependent recruitment of CK2 in the NMDAR subunit switch, it remains possible that CK2 could still play a role in phosphorylating GluN2B Ser-1480, disrupting its interactions with MAGUKs, leading to reduced surface expression ([@bib12]) independent of the GluN2B CaMKII site. We considered investigating the influence of the CK2 inhibitor TBB, used previously to implicate CK2 in the switch. However, TBB is known to inhibit kinases DYRK1A, DYRK2, DYRK3, PIM2, PIM3, and HIPK2 just as effectively as it inhibits CK2 ([@bib38]). Indeed, the TBB target DYRK1A has been shown to phosphorylate and positively influence the surface expression of GluN2A ([@bib19], [@bib1]). Thus, DYRK1A inhibition by TBB could conceivably reduce GluN2A levels via this mechanism. Another potential issue is TBB cytotoxicity ([@bib43]), so deletion of CK2 may be a better approach to directly probe its role in NMDAR subunit switching.

Interdependence of GluN2B Phosphorylation Sites {#sec3.2}
-----------------------------------------------

Our observations align with predictions based on previous studies ([@bib51]) that mutation of the GluN2B CaMKII site would reduce Ser-1480 phosphorylation (a CK2 site; [@bib50]) and increase Tyr-1472 phosphorylation (a Fyn site; [@bib37]). However, although increased Fyn-driven Tyr-1472 phosphorylation prevents AP-2-mediated GluN2B endocytosis ([@bib41], [@bib45], [@bib59]), we did not observe increased synaptic GluN2B in GluN2B^ΔCaMKII/ΔCaMKII^ neurons. One possible explanation is that the changes in phosphorylation we observe (around 30%) were too small to have a significant effect on synaptic GluN2B levels. Indeed, constitutive activation of Fyn increased synaptic GluN2B-mediated NMDAR currents by only around 15%, and a similar difference was observed under basal conditions between GluN2B and non-phosphorylatable GluN2B-Y1472A overexpressing neurons ([@bib41]). In a similar vein, the reduction in endocytosis observed in ectopically expressed GluN2B-Y1472A compared to ectopically expressed WT GluN2B is around 25% ([@bib50]). Thus, the changes observed even when driving the system maximally by expressing mutant subunits and constitutively active kinases are quite modest, meaning that the relatively small changes in Y-1472 phosphorylation may not have a detectable effect on synaptic GluN2B expression.

The GluN2B CaMKII Site in Synaptic Plasticity {#sec3.3}
---------------------------------------------

Our findings regarding normal excitatory synaptogenesis and synaptic transmission in the GluN2B^ΔCaMKII/ΔCaMKII^ mouse are consistent with observations made in an independently created knockin mouse with a targeted mutation of the GluN2B CaMKII site ([@bib20]). One observation where our data do not align is their reporting of a deficit (ca. 30%) in theta-burst LTP, which we did not observe. One difference in our knockin lines is our additional mutation (the phospho-mimetic S1303D), chosen because, although R1300Q and S1303D both reduce CaMKII-GluN2B interaction, the double mutant R1300Q/S1303D reduces binding even further ([@bib53]). The inclusion of the S1303D in GluN2B "CaMKII site" mutants has been employed elsewhere ([@bib2], [@bib18], [@bib55]) but will alter the charge at this site. However, whatever the approach used to disrupt CaMKII binding, alteration of the charge at Ser-1303 is likely to be unavoidable, because CaMKII is the major kinase at this site and forebrain neurons have substantial basal S1303 phosphorylation ([@bib35]), which will likely decrease if CaMKII association is disrupted. It is therefore likely that mutating L1298 and R1300 alone may lower S1303 phosphorylation ([@bib20]), reducing the negative charge at this site, and our mutation of S1303D will increase the charge. Thus, although there is no evidence that the charge at S1303 has additional effects, this difference between the two knockin models could explain the discrepancy in the LTP experiments and requires further investigation.

Concluding Remarks {#sec3.4}
------------------

Our observations argue against a central role for CTD subtype-specific events in the normal developmental subunit shift in cortical NMDAR subunit composition and that an increase in GluN2A expression is likely the major driver of GluN2A:GluN2B ratio increases. Thus, although GluN2 subtype-specific CTD sequences do influence excitotoxicity, plasticity, protein complex formation, and behavioral repertoire ([@bib17], [@bib33], [@bib49]), their role in directing neuronal development and maturation may be less pronounced.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------
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Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Giles Hardingham (<Giles.Hardingham@ed.ac.uk>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Animals {#sec4.3.1}

All animal experiments conformed to national and institutional guidelines including the Animals \[Scientific Procedures Act\] 1986 (UK), and the Council Directive 2010/63EU of the European Parliament, and had full Home Office ethical approval. All animals were maintained in pathogen-free and light- (12hr light/ 12hr dark) and temperature-controlled conditions. Food and water were available *ad libitum.* Animals were group-housed in conventional cages and were provided with environmental enrichment. Animals had not been subject to previous procedures. P14 and P28 homozygous and wild-type mice of both sexes were used and were generated as a result of heterozygous intercrosses to generate littermate controls. GluN2A^2B(CTR)/2B(CTR)^ and GluN2B^ΔCaMKII^ mice were maintained on a C57BL/6J background. GluN2A^−/−^ rats were maintained on a Long Evans Hooded background, and E20.5 rats of all genotypes were generated as a result of heterozygous intercrosses.

### Primary cultures {#sec4.3.2}

Cortical mouse and rat neurons were cultured as described ([@bib42]) at a density of 9-13 × 10^4^ neurons per cm^2^ from E17.5 mice or E20.5 rats (mixed sexes) with Neurobasal growth medium supplemented with B27 (Invitrogen, Paisley, UK). The cultures were maintained at 37°C with 5% CO2. Experiments were performed at DIV 8-18 as indicated. By DIV 8 the neurons are capable of supporting synchronous synaptic activity, but NMDA receptors are primarily GluN2B-containing, whereas at DIV 18 there is a substantial GluN2A component ([@bib5], [@bib34]).

#### Generation of the GluN2B^ΔCaMKII^ and mouse {#sec4.3.2.1}

GluN2A^2B(CTR)/2B(CTR)^ neurons ([@bib49]) were produced from GluN2A^2B(CTR)/2B(CTR)^ embryos resulting from GluN2A^WT/2B(CTR)^ x GluN2A^WT/2B(CTR)^ mating, which also yielded GluN2A^WT/WT^ littermate controls. Specific details regarding the generation of GluN2A^2B(CTR)^ line can be found elsewhere ([@bib49]). The GluN2A^WT^ allele was genotyped using primers (5′-CTTCTTTTCTTCAATGTGCACTCC −3′) and (5′-CTACATCATCAGAAGCCCACC −3′) while the GluN2A^2B(CTR)^ allele was genotyped using primers (5′-GGGGAAGTTACATGGTGGATTG-3′) and (5′-GGGATGATCAGTGCTTGCTTC-3′).

#### Generation of the GluN2B^ΔCaMKII^ mouse {#sec4.3.2.9}

An artificial polylinker containing Xho1 and HindIII restriction sites was inserted into the NotI and SalI sites of pSP72 (Promega), resulting in pSP72-L. A Diphtheria Toxin A (DT-A) fragment driven by an MC1 promoter with a mouse SV40 polyadenylation signal was digested with HindIII and XhoI, and inserted into the HindIII and SalI sites of pSP72-L, creating pSP72-L-DT-ApA ([@bib58]). A previously generated GluN2B targeting vector was acquired and co-opted for construction of the GluN2B-CaMKII vector ([@bib14]). The GluN2B-CaMKII targeting vector included a neomycin phosphotransferase gene (Neo) driven by a compound phosphoglycerate kinase (PGK) and EM7 promoter for kanamycin resistance in bacteria, and G418 resistance in murine cells, respectively. Substitutions were introduced into the GluN2B 3′ terminal exon by mutagenic PCR using primers, resulting in the GluN2B-CaMKII vector. The GluN2B-CaMKII vector was then inserted into the NotI and XhoI sites of pSP72-L-DT-ApA, generating the final GluN2B S1303D targeting vector. The targeting vector was linearized with NotI and electroporated into E14Tg2A (129/OlaHsd) mouse embryonic stem (ES) cells ([@bib24]). ES cells colony selection was carried out using G418. Genomic DNA was extracted from individually picked ES cell colonies and used for screening for targeting vector integration by long-range PCR using primers P1 (ACGAGATCAGCAGCCTCTGTTCCAC) and P2 (GAGGCGGGGCGACCAGGAAGGC). P1, hybridizes to the Neo cassette, P2 hybridizes to a region of genomic DNA that is 3′ of the targeting vector 3′ homology arm. The GluN2B C-terminal exon was cloned from targeted ES cell lines and sequenced to confirm the presence of the mutated sites (data not shown). ES cell clones were injected into C57BL/6J mouse blastocysts, which were then implanted into a pseudopregnant mouse. Chimeras were identified from the offspring based on coat color. Male chimeras were crossed onto C57BL/6J females in order to obtain an F1 generation. Genomic DNA was extracted from F1 progeny and used for confirmation of germline transmission by PCR using primers P1 and P2, and primers P3 (TCAGTGCTTGCTTCACGGCAGC) and P4 (CTCCTCTCCAGCCTCCCACACT). P3 hybridizes to the GluN2B C-terminal domain exon, and P4 to the NR2B 3′ UTR. F1 heterozygotes were crossed onto transgenic mice expressing Cre recombinase under a CMV promoter to excise the Neo selection cassette. Neo removal in the F2 generation was assessed by PCR using primers P3 and P4, which gives a 567 bp product for wild-type mice and a 628 bp product for mutant alleles without the Neo cassette, and P4 and P5 (TGGAAGGATTGGAGCTACGGG), which gives a ∼700 bp product only if the Neo cassette is present. Mice were genotyped using primers P3 and P4. The line was further backcrossed onto C57BL/6J for 6 generations prior to the commencement of experiments. Animals were treated in accordance with UK Animal Scientific Procedures Act (1986). All the experiments were performed using wild-type and homozygous littermates.

#### Generation of the GluN2A^--/--^ rat {#sec4.3.2.2}

Single cell Long Evans Hooded rat embryos underwent pronuclear microinjection of mRNA encoding the enzyme Cas9 and small guide RNAs (sgRNA) binding to 5′ and 3′ of exon 8 of Grin2A, before being implanted into pseudopregnant mothers. The resulting live births were screened by PCR for genomic deletions due to repair by non-homologous end joining of double stranded breaks targeted to either side of exon 8. A 1065bp deletion spanning exon 8 (which encodes key pore forming domains of GluN2A) was identified, and confirmed by sequencing (data not shown). Genotyping was performed using primer pairs P5 (AGGGAAGAAGGGAACAGGAG) with P6 (TCTCTGGGATTCAGTGCAGA) and P7 (AAGGCAGAGAGAGAGACAAAG) with P8 (ATGGCAGTTCCCAGTAGCAT). P5 and P7 bind to 5′ of the deletion, P6 binds to 3′ of the deletion, and P8 binds within the deletion. The sgRNA design and generation of the founder animals were performed by Horizon Discovery Group plc (St Loius, MO, USA). Animals were treated in accordance with UK Animal Scientific Procedures Act (1986). All the experiments were performed using wild-type, heterozygous, and homozygous littermates matched animals.

Method Details {#sec4.4}
--------------

### Cell culture electrophysiological recording and analysis {#sec4.4.1}

Whole cell patch clamp recordings were performed as described ([@bib15], [@bib22]). Briefly, coverslips containing cortical neurons were transferred to a recording chamber perfused (at a flow rate of 3-5 ml/min) with an external recording solution composed of (in mM): 150 NaCl, 2.8 KCl, 10 HEPES, 2 CaCl~2~, 10 glucose and 0.1 glycine, pH 7.3 (320-330 mOsm). Tetrodoxin (300 nM) was included to block action-potential driven excitatory events. Patch-pipettes were made from thick-walled borosilicate glass (Harvard Apparatus, Kent, UK) and filled with a K-gluconate-based internal solution containing (in mM): potassium gluconate 141, NaCl 2.5, HEPES 10, EGTA 11; pH 7.3 with KOH). Electrode tips were fire-polished for a final resistance ranging between 3-5 MΩ. All NMDA currents were evoked by 150 μM NMDA and 100 μM glycine, bath applied using a perfusion system. Currents were recorded at room temperature (21 ± 2°C) using an axopatch 200B amplifier (Molecular Devices, Union City, CA). Neurons were voltage-clamped at --60 mV and recordings were rejected if the holding current was greater than --100 pA or if the series resistance drifted by more than 20% of its initial value (\< 20 MΩ). Whole-cell currents were analyzed using WinEDR v3.2 software (John Dempster, University of Strathclyde, UK).

To measure extrasynaptic NMDAR currents, synaptically-located NMDARs were blocked by the use-dependent antagonist MK-801, in an activity-dependent manner as previously described ([@bib33]). First, whole-cell NMDAR currents were recorded in voltage-clamp (150 μM NMDA, in Mg^2+^-free and TTX containing recording solution). Neurons were then switched to current-clamp mode in normal Mg^2+^-containing, TTX-free medium in the presence of MK-801 (10 μM) and bicuculline (50 μM). After 5 minutes of neuronal firing, the neurons were switched back to voltage clamp and the whole-cell NMDA currents were re-assessed as above; the slow off-rate of MK-801 ensures synaptic NMDARs remained blocked and only extrasynaptic NMDAR currents are recorded.

To determine the ifenprodil-sensitivity of neurons, whole cell NMDA currents were recorded followed by the inclusion of 3 μM ifenprodil in the recording solution for a blocking period of 90 s. The whole cell NMDA current was the re-assessed, with 3 μM ifenprodil included, and the % block calculated.

For determining spermine potentiation, neurons were initially voltage-clamped at −60mV using the internal solution and ACSF described above. The neurons were then voltage clamped at −30 mV and switched to a recording solution composed of (in mM): 70 NaCl, 60 choline chloride, 2.8 KCl, 20 HEPES, 10 glucose, 0.1 glycine, pH 6.5. 100 μM pentetic acid was also included otherwise rapid desensitization of the spermine potentiation occurred. NMDA currents were evoked (as described above) then potentiated by 100 μM and 200 μM spermine consecutively. 200 μM spermine was originally included as an internal control: both 100 μM and 200 μM spermine are on the linear part of the dose-response and an approximate 2-fold increase in potentiation was expected jumping from 100 μM to 200 μM spermine.

### Slice electrophysiological recordings and analysis {#sec4.4.2}

For extracellular and EPSC recordings illustrated in [Figures 2](#fig2){ref-type="fig"}D--2I, [S2](#mmc1){ref-type="supplementary-material"}B, and S2C, mice were deeply anaesthetised with halothane and then sacrificed by cervical dislocation using techniques approved by UCLA Institutional Animal Care and Use Committee. Following the dissection of the hippocampi from the rest of the brain, 400 μm thick hippocampal slices were cut using a manual tissue chopper and then maintained at 30°C in an interface-slice type recording chamber perfused with oxygenated (95% O~2~/5% CO~2~) artificial cerebrospinal fluid (ACSF) containing 124 mM NaCl, 4.4 mM KCl, 25 mM NaHCO~3~, 1 mM NaH~2~PO~4~, 2 mM CaCl~2~, 1.2 mM MgSO~4~, and 10 mM glucose. Whole-cell voltage-clamp techniques were used to record AMPA receptor- and NMDA receptor-mediated excitatory postsynaptic currents (EPSCs). In these experiments, slices were bathed in a modified ACSF containing 4.0 mM CaCl~2~, 4.0 mM MgSO~4~, 2.4 mM KCl, and 100 μM picrotoxin. The CA3 region was removed to prevent bursting in the absence of inhibition and slices were maintained at 30°C in a submerged slice recording chamber. Recording electrodes (3--6 MOhms) were filled with a solution containing 102 mM cesium gluconate, 17.5 mM CsCl, 10 mM TEA-Cl, 5 mM QX314, 4.0 mM Mg-ATP, 0.3 mM Tris-GTP, and 20 mM HEPES (pH = 7.2). EPSCs evoked by Schaffer collateral fiber stimulation at 0.2 Hz were recorded at membrane potentials of −80 mV or +40 mV, and the AMPA receptor- and NMDA receptor-mediated components of the synaptic currents were estimated by measuring EPSC amplitude 5 and 50 ms after EPSC onset, respectively. In these experiments, the intensity of presynaptic fiber stimulation was adjusted to elicit EPSCs with peak amplitudes of approximately 200 pA at −80 mV. Spontaneous miniature EPSCs were recorded at −80 mV in the presence of 1.0 μM TTX. A combination of template and threshold (6 pA) based event detection routines in pClamp 10 (Molecular Devices) was used for mEPSC analysis. Extracellular recordings ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C) were done under interface conditions and began after allowing the slices to recover for at least 1 hour. In the experiments illustrated in [Figures 2](#fig2){ref-type="fig"}J, 2K, and [S2](#mmc1){ref-type="supplementary-material"}A, fEPSPs were recorded by using microelectrode arrays (MEA60, Multi Channel Systems, Reutlingen, FRG). Input/output relationships and theta-burst stimulation-induced LTP were examined using hippocampal slice preparations and experimental conditions described in detail previously ([@bib27]). Theta-burst stimulation consisted of 10 bursts of 100 Hz stimulation (4 pulses) delivered with an inter-burst interval of 200 ms. The magnitude of LTP present 60--65 minutes post theta-burst stimulation was used for statistical comparisons.

### PSD fractionation, co-immunoprecipitation and western blotting {#sec4.4.3}

To isolate PSD-enriched proteins (containing synaptic NMDARs) and we used an approach previously described for studying synaptic and extrasynaptic NMDAR populations ([@bib33]). Briefly, brains from P14 and P28 mice were dissected, their cortices removed and immediately placed in ice-cold homogenization buffer (10 mM Sucrose, 10 mM HEPES, supplemented with Protease and Phosphatase Inhibitor Cocktail tablets (Roche, Burgess Hill, UK), pH 7.4). Tissue samples were homogenized with a teflon/glass homogenizer then centrifuged (1,000 g, 10 min, 4°C). The supernatant was collected and centrifuged at 12,000 g (20 min, 4°C), after which the pellet was resuspended twice in 4mM HEPES (containing 1mM EDTA, pH 7.4) by repeating the last centrifugation step. To obtain the non-PSD enriched fraction, pellets were then resuspended in 20 mM HEPES, 100 mM NaCl and 0.5% Triton X-100 (pH 7.2). Samples were incubated 15 min at 4°C while rotating gently, followed by centrifugation (12,000 g, 20 min, 4°C). The supernatant was collected (Non-PSD enriched fraction) and the pellet solubilized (in 20 mM HEPES, 0.15 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate (DOC), 1% SDS, 1 mM DTT, pH 7.5) for a further 1h at 4°C with gentle agitation. Finally, the samples were centrifuged at 10,000 g for 15 min (4°C) and the supernatants were collected as PSD-enriched fractions. Fractions were stored at −20°C until western blotting, and used less than two weeks after preparation.

For co-immunoprecipitation, P28 cortices were homogenized in IP buffer (50 mM Tris HCl pH 9, 50 mM NaF, 20 μM ZnCl~2~, 1 mM Na~3~VO~4~, 1:100 protease inhibitor cocktail set III (Merck Chemicals, Nottingham, UK), 0.5 mg/ml PMSF, 1% DOC) and centrifuged for 40 min at 25000 g. The protein concentration in the supernatant was measured (by BCA assay) and adjusted to 3.5 mg/ml using IP buffer. Antigen binding was carried-out by adding of 2 μg of antibody (anti-GluN2B (N terminus,), or control IgG) to 1.75 mg of protein extract. The antibody-antigen mixture was incubated overnight with rotation at 4°C. 50 μl Dynabeads® were used per immunoprecipitation reaction incubation, and were aliquoted to each antigen-antibody mixture. Beads were incubated with the antibody for 20 min at room temperature on a rotator. The Dynabead-antibody-antigen complex was then washed four times in IP buffer, before being eluted by suspending the beads in 40 μL of 1.5x 40 μL of 1.5x LDS sample buffer (NuPage, Life Technologies) and boiling for 10 min. The supernatant was then stored at −80°C until SDS-PAGE and western blotting was carried out.

For western blotting, a procedure similar to that previously described was employed ([@bib4]). In order to minimize the chance of post-translational modifications during the harvesting process, neurons were lysed immediately after stimulation in 1.5x LDS sample buffer (NuPage, Life Technologies) and boiled at 100°C for 10 min. Approximately 10 μg of protein was loaded onto a precast gradient gel (4%--12%) and subjected to electrophoresis. Briefly, western blotting onto a PVDF membrane was then performed using the Xcell Surelock system (Invitrogen) according to the manufacturer's instructions. Following the protein transfer, the PVDF membranes were blocked for 1 hour at room temperature with 5% (w/v) non-fat dried milk in TBS with 0.1% Tween 20. The membranes were incubated at 4°C overnight with the primary antibodies diluted in blocking solution: anti phospho-(Ser-1303) GluN2B (1: 2000, Millipore), anti-phospho (Tyr-1472) GluN2B (1:2000, Millipore), anti-phospho (Ser1480) GluN2B (1:2000, Abcam), anti-GluN2B (C terminus, 1:4000, BD Transduction Laboratories), anti-GluN2B (N terminus 1:2000, Thermo Fisher Scientific), anti-GluN2A (N terminus, 1:1000, Thermo Fisher Scientific), anti-CamKiiα (1:8000, Thermo Fisher Scientific), anti-ERK1/2 (1:2000, Cell Signaling), anti-phospho ERK1/2 (1:2000, Cell Signaling) and anti-beta actin (1:200000, Abcam). For visualization of western blots, HRP-based secondary antibodies were used followed by chemiluminescent detection on Kodak X-Omat film. Western blots were digitally scanned and densitometric analysis was performed using ImageJ. All analysis involved normalizing to either GluN2B (for phospho-GluN2B antibodies) or beta actin expression as a loading control.

### Transfection of cortical neurons {#sec4.4.4}

Neurons were transfected at DIV 7 using Lipofectamine 2000 (Invitrogen) according to the manufacturer's suggested protocol as previously described ([@bib8]). β-globin or pCis-GluN2A ([@bib47]) were co-transfected with enhanced green fluorescent protein (eGFP), to identify transfected cells, in a ratio of 2:1. Transfection efficiency was approximately 5% with \> 99% of eGFP-expressing cells being identified as positive for the neuronal nuclear antigen (NeuN), while \< 1% were positive for glial fibrillary acidic protein (GFAP) ([@bib23]). Electrophysiological recordings were made from transfected neurons 72-96 h post transfection.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

### Statistical analysis, equipment and settings {#sec4.5.1}

Statistical testing involved a 2-tailed paired Student's t test., or a one- or two-way ANOVA followed by Sidak's post hoc test. Cell death analyses for both *in vitro* and *in vivo* experiments were performed blind to the genotype/experimental condition. For western blots, we used chemiluminescent detection on Kodak X-Omat film, and linear adjustment of brightness/contrast applied (Photoshop) equally across the image, maintaining some background intensity. In some cases, lanes from non-adjacent lanes are spliced together, but the lanes are always from the same blot, processed in the same way, and the splicing point is clearly marked. For the analysis of electrophysiological data in MEA-based recordings ([Figures 2](#fig2){ref-type="fig"}J, 2K, and [S2](#mmc1){ref-type="supplementary-material"}A), because several slices were routinely recorded from every mouse, the values of the area under the I/O relationship (AUC~I/O~), values of peak fEPSP amplitudes evoked by maximum stimulus strength and LTP in WT and mutant mice were compared by the two-way nested ANOVA with genotype (group) and mice (sub-group) as fixed and random factors, correspondingly, with the Satterthwaite's correction applied to calculate effective degrees of freedom (STATISTICA v. 10, StatSoft, Inc., Tulsa, OK, USA). Statistical effects were considered significant if p \< 0.05. Statistical details of each experiment can be found within figure legends.

Supplemental Information {#app2}
========================

Document S1. Figures S1--S3Document S2. Article plus Supplemental Information

We thank Kathryn Elsegood, Lynsey Robertson, David Fricker, and Chih-yuan Chiang for mouse colony management and genotyping. Work in the G.E.H. lab is supported by the MRC, Wellcome Trust, Alzheimer's Research UK, and Alzheimer\'s Society. Work in the S.G.N.G. lab is supported by a Wellcome Technology Development Grant (202932) and an European Research Council Advanced Grant (695568).

Author Contributions {#sec5}
====================

Project Conceptualization, N.H.K., S.G.N.G., T.J.R., and G.E.H.; Supervision and Project Administration, N.H.K., G.E.H., S.G.N.G., T.J.O., D.J.A.W., and P.C.K.; Experimental Work, S.M., T.J.R., J.M., T.I., K.F.M.M., P.H., M.V.K., P.S.B., and M.-A.M.; Data Analysis, S.M., T.J.R., J.M., T.I., K.F.M.M., P.H., M.V.K., P.S.B., M.-A.M., T.J.O., G.E.H., and N.H.K.; Writing -- Original Draft, G.E.H.; Writing -- Review & Editing, all authors.

Declaration of Interests {#sec6}
========================

The authors declare no competing interests.

Supplemental Information includes three figures and can be found with this article online at [https://doi.org/10.1016/j.celrep.2018.09.089](10.1016/j.celrep.2018.09.089){#intref0080}.

[^1]: These authors contributed equally

[^2]: Lead Contact
